Multiple myeloma maintenance therapy: A review of the pharmacologic treatment
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Multiple myeloma maintenance therapy: A review of the pharmacologic treatment
Authors
Keywords
-
Journal
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Volume 21, Issue 1, Pages 36-51
Publisher
SAGE Publications
Online
2014-01-07
DOI
10.1177/1078155213514468
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma
- (2012) Giovanni Barosi et al. ANNALS OF HEMATOLOGY
- Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
- (2012) M.-V. Mateos et al. BLOOD
- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
- (2012) R. Vij et al. BLOOD
- Second malignancies after multiple myeloma: from 1960s to 2010s
- (2012) A. Thomas et al. BLOOD
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- IMWG consensus on maintenance therapy in multiple myeloma
- (2012) H. Ludwig et al. BLOOD
- Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
- (2012) L. Rosinol et al. BLOOD
- Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center
- (2012) W Bensinger et al. BONE MARROW TRANSPLANTATION
- Role of autologous bone marrow transplant in multiple myeloma
- (2012) Margarita Blanes et al. CURRENT OPINION IN ONCOLOGY
- Bone Marrow Microenvironment in Multiple Myeloma Progression
- (2012) S. Manier et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
- (2012) Laurent Garderet et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
- (2012) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
- (2011) K. Neben et al. BLOOD
- Approach to the treatment of multiple myeloma: a clash of philosophies
- (2011) S. V. Rajkumar et al. BLOOD
- The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
- (2011) G. J. Morgan et al. BLOOD
- Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
- (2011) E. Kneppers et al. BLOOD
- Guidelines for the diagnosis and management of multiple myeloma 2011
- (2011) Jennifer M. Bird et al. BRITISH JOURNAL OF HAEMATOLOGY
- Carfilzomib: a novel second-generation proteasome inhibitor
- (2011) Meaghan L Khan et al. Future Oncology
- Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
- (2011) Amrita Krishnan et al. LANCET ONCOLOGY
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens
- (2010) Giulia Benevolo et al. CANCER
- Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma
- (2010) H. Ludwig et al. HAEMATOLOGICA
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma
- (2010) Henk Lokhorst et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
- (2010) María-Victoria Mateos et al. LANCET ONCOLOGY
- Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial
- (2010) A Dispenzieri et al. LEUKEMIA
- A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
- (2009) H. M. Lokhorst et al. BLOOD
- Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen
- (2009) James R. Berenson et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
- (2009) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure
- (2009) Andrew Spencer et al. JOURNAL OF CLINICAL ONCOLOGY
- Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
- (2008) B. Barlogie et al. BLOOD
- A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma
- (2008) Lisa K. Hicks et al. CANCER TREATMENT REVIEWS
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
- (2008) R A Kyle et al. LEUKEMIA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started